Pagina 1 a partire dal 62 risultati
Diabetic macular edema (DME) causes significant visual loss in diabetic patients. About 20% and 40% of patients with Type 1 and Type 2 diabetes mellitus (DM), respectively, develop DME. One-third of diabetic patients who have had DM for more than twenty years will develop DME . Early impairment in
PhD project description
The arterial wall in patients with diabetes: Do changes in arterial basement membrane proteins predict future arterial disease? Are remodeling processes altered?
Applicant: Anne-Sofie Faarvang Thorsen1, MD
Main supervisor: Professor Lars Melholt Rasmussen1
Co-supervisors:
Purpose of our study investigation of the effects foot exercises in patients with type 2 diabetic and peripheral neuropathy.
Excepted results: Routine treatment + foot exercises pain, flexibility, edema, muscle strength, sensation, quality of life we believe that there will be good progress in
Introduction. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are prioritized as a second-line therapy for the treatment of type 2 diabetes (T2D), especially in patients with a history of cardiovascular disease (CVD) or when there is a need to avoid weight gain and hypoglycemia. Randomized
In this single-centre, open label study, 300 adults with DN will be recruited over 3 years. Following screening and baseline metabolic evaluations, eligible subjects will be treated with fenofibrate for 30-days and re-assessed.
4.1 Study Visits and Procedures Subjects will have their written
As part of the central nervous system (CNS), the retina shares key structural and functional features with the brain, making it a potential portal into a patient's medical future. Since the cerebral and retinal microvasculature are strikingly similar, the condition of retinal vasculature has been
Diabetic Retinopathy (DR) is a frequent complication of Diabetes Mellitus (DM) and is the main cause of vision loss in the working population in western countries.
Several studies provided evidence that good diabetic control is important to prevent and delay disease progression, but while some
The worldwide prevalence of diabetic macular edema was reported as 6.81% among patients with diabetes. Other research reported that the 10-year incidence of diabetic macular edema was 14% in individuals with type 2 diabetes, and progression to diabetic macular edema occurred in 29% of individuals
This is a prospective, randomized, double-masked, multicenter, Phase I/II clinical study in which up to 40 eligible subjects with active Diabetic Macular Edema (DME) will be randomized to 1 of 2 treatment arms in a 1:1 ratio as follows: SF0166 low dose twice daily (BID) or SF0166 high dose BID.
The